Thus, the relative levels of Myc versus NF-κB signaling factors (and perhaps the timing of Myc over-expression in B cells) may determine whether Myc and NF-κB collaboratively induce NF-κB driven DLBCL-like lymphomas or instead NF-κB inhibits Myc-driven BL-like lymphomas in transgenic mouse models. The gene discussed is MYC; the disease is lymphoma.